Kailera Therapeutics, Inc. (KLRA) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of Kailera Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KLRA
Kailera Therapeutics, Inc.
$10.76HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.63HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — KLRA vs RARE
growth of $100 · dividends reinvested · last 1yKLRA -58.3% (-58.3%/yr)RARE -42.4% (-42.4%/yr)RARE compounded faster over this window
KLRA RARE
KLRA vs RARE: by the numbers
- •RARE is the larger company ($1.44B vs $1.39B market cap).
- •Both run net losses; KLRA's is the smaller (0.00% vs -81.79% net margin).
Metrics side by side
Valuation
| Metric | KLRA | RARE |
|---|---|---|
| P/S ratio | N/A | 2.01 |
| P/B ratio | 1.25 | N/A |
Profitability
| Metric | KLRA | RARE |
|---|---|---|
| Gross margin | 0.00% | 83.12% |
| Operating margin | 0.00% | -73.77% |
| Net margin | 0.00% | -81.79% |
| ROIC | -24.52% | -53.48% |
Growth (annualized)
| Metric | KLRA | RARE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 14.81% |
| Total return CAGR (5Y) | N/A | -30.14% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.